Zacks Research Has Bullish Estimate for Integer Q3 Earnings

Key Points

• Zacks Research has raised its Q3 2025 earnings estimate for Integer Holdings Corporation to $1.68 per share, which is an increase from the previous estimate of $1.67.
• Integer reported earnings of $1.55 per share last quarter, which fell short of the consensus estimate of $1.57, although its revenue of $476 million surpassed expectations.
• Despite recent price target reductions from various analysts, Integer holds a Moderate Buy rating overall with a consensus price target of $140.25.

Integer Holdings Corporation (NYSE:ITGR - Free Report) - Research analysts at Zacks Research upped their Q3 2025 earnings estimates for Integer in a note issued to investors on Thursday, August 14th. Zacks Research analyst Team now forecasts that the medical equipment provider will post earnings of $1.68 per share for the quarter, up from their prior estimate of $1.67. The consensus estimate for Integer's current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer's Q4 2025 earnings at $1.83 EPS, FY2025 earnings at $6.37 EPS, Q1 2026 earnings at $1.58 EPS, Q2 2026 earnings at $1.75 EPS, Q3 2026 earnings at $1.85 EPS, Q4 2026 earnings at $1.93 EPS, FY2026 earnings at $7.10 EPS, Q1 2027 earnings at $1.77 EPS, Q2 2027 earnings at $1.94 EPS and FY2027 earnings at $7.73 EPS.

ITGR has been the subject of several other research reports. Benchmark decreased their price target on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 25th. Truist Financial decreased their target price on Integer from $145.00 to $137.00 and set a "buy" rating for the company in a research note on Friday, July 25th. Citigroup raised Integer from a "hold" rating to a "strong-buy" rating and raised their price target for the stock from $133.00 to $140.00 in a research report on Thursday, May 22nd. Wells Fargo & Company cut their price target on shares of Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Finally, Raymond James Financial lowered their price objective on shares of Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research report on Friday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $140.25.

Integer Trading Up 0.3%

Integer stock traded up $0.35 during midday trading on Monday, hitting $107.65. 75,857 shares of the stock were exchanged, compared to its average volume of 479,904. The stock has a market capitalization of $3.77 billion, a PE ratio of 47.41, a P/E/G ratio of 0.84 and a beta of 1.02. The company has a fifty day simple moving average of $114.15 and a two-hundred day simple moving average of $119.62. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. Integer has a 52 week low of $104.93 and a 52 week high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.02). The firm had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The company's revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS.

Insider Activity at Integer

In other Integer news, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the sale, the director directly owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This represents a 28.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Donald J. Spence sold 14,739 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the transaction, the director directly owned 18,781 shares in the company, valued at approximately $2,260,856.78. This trade represents a 43.97% decrease in their position. The disclosure for this sale can be found here. 2.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Integer

A number of large investors have recently added to or reduced their stakes in ITGR. Wealth Enhancement Advisory Services LLC bought a new position in Integer during the fourth quarter worth $208,000. Teacher Retirement System of Texas bought a new position in Integer in the 1st quarter valued at about $579,000. Northern Trust Corp lifted its position in Integer by 14.2% during the fourth quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider's stock worth $55,974,000 after acquiring an additional 52,556 shares during the last quarter. MQS Management LLC bought a new stake in shares of Integer during the first quarter worth approximately $272,000. Finally, Sterling Capital Management LLC grew its position in shares of Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 279 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.